GSK’s benign prostatic hyperplasia (BPH) drug ‘Duodart (dutasteride+tamsulosin)’ has been making rapid growth in the outpatient prescription market in Korea.

Until now, the market for combination drugs in the field of urology was considered barren. Unlike other chronic disease areas, combination drugs are rare in the area. Companies have been dropping the development of their combo drugs shortly before commercialization due to low marketability.

This is why the industry is focused on the success of Duodart’s soft landing in the Korean market. If Duodart paves the way and makes success as a combination drug in the field of urology, the industry believes it will encourage the developme